Table 1. Clinical characteristics of the studied cohort.
| METHAMPHETAMINE | NO | YES |
| History of abuse/dependence | (HIV+METH−) | (HIV+METH+) |
| Number of subjects | 14 | 13 |
| Age at death, mean (SD) | 46 (6) | 45 (10) |
| Gender (M/F) | 13/1 | 11/2 |
| Neurocognitive status, NP rating (%) | ||
| Normal | 1 (7) | 5 (38) |
| NPI-O | 8 (57) | 2 (15) |
| ANI | 1 (7) | 0 |
| MND | 4 (29) | 5 (38) |
| HAD | 0 | 1 (9) |
| Exposure to ARV, months (SD) | 9.2 (6) | 23.3 (42) |
| Log plasma HIV copy/ml, mean (SD) | 4.3 (0.9) | 4.7 (1.5) |
| Log CSF HIV copy/ml, mean (SD) | 2.4 (0.8) | 2.6 (0.8) |
| CD4+ lymphocytes/mm3, mean (SD) | 94 (144) | 109 (237) |
| METH Abuse (%)/Dependence (%) | 0 (0)/0 (0) | 13 (100)/13 (100) |
| Alcohol Abuse (%)/Dependence (%) | 5 (36)/2 (14) | 6 (46)/8 (62) |
| Cannabis Abuse (%)/Dependence (%) | 2 (14)/0 (0) | 8 (62)/3 (23) |
| Cocaine Abuse (%)/Dependence (%) | 1 (7)/0 (0) | 4 (31)/3 (23) |
| Opiate Abuse (%)/Dependence (%) | 0 (0)/1 (7) | 1 (8)/1 (8) |
| Sedative Abuse (%)/Dependence (%) | 0 (0)/1 (7) | 2 (15)/1 (8) |
| Other Drugs Abuse (%)/Dependence (%) | 0 (0)/0 (0) | 2 (15)/2 (15) |
NPI-O, neurocognitive impairment due to a cause other than HIV; ANI, asymptomatic neurocognitive disorder; MND, mild neurocognitive disorder; HAD, HIV-associated dementia.